Reminder: biosimilars policy in Quebec
As you may know, a biosimilar drug policy was implemented in Quebec in May 2021. The goal of this policy is to transition insureds who are taking a reference biologic drug to the biosimilar version of that drug. At the end of the transition period, on April 12, 2022, reference biologic drugs will no longer be reimbursed by the Régime général d'assurance médicaments1 (not included in the List of medications).
As announced last fall, all plan members taking reference biologic drugs targeted by the provincial policy received personalized communications about this. These communications provided information on biosimilar drugs and included specific details regarding reimbursement of their biologic drug.
In addition to being less expensive than reference biologics, biosimilar drugs offer additional options to plan members and therefore facilitate access to certain treatments. Furthermore, biosimilar drugs are comparable to biologics and there are no clinically significant differences in efficacy and safety between the two.
If you have any questions, please contact your advisor or your iA Financial Group Account Executive.1 There are exceptions for pregnant women, people under 18 years of age, or people for whom two or more other biologic drugs have failed.